> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Guide on Depot Buprenorphine Product Development
- URL: https://www.fdaweb.com/guide-on-depot-buprenorphine-product-development-2/
- Published: 2019-02-08T12:00:00.000Z
- Updated: 2026-09-15T01:01:52.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5143339

*Federal Register* notice: FDA has made available a final guidance entitled “Opioid Use Disorder: Developing Depot Buprenorphine Products for Treatment.” The document outlines the agency’s perspective on drug product development and trial design issues relevant to the study of depot buprenorphine products (i.e., modified-release products for injection or implantation). To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2019-02-07/pdf/2019-01517.pdf?ref=fdaweb.com).